A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Rezpegaldesleukin (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Proof of concept
- Sponsors Eli Lilly and Company
Most Recent Events
- 12 Mar 2025 According to a Nektar Therapeutics media release, data from the study were presented in Nature Communications.
- 06 Sep 2022 Results presented in a Nektar Therapeutics media release.
- 06 Sep 2022 According to a Nektar Therapeutics media release, data from the trial are being presented at the 2022 European Academy of Dermatology and Venereology (EADV) Congress.